Milovanovic S R, Radulovic S, Schally A V
Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, New Orleans, LA 70146.
Breast Cancer Res Treat. 1992;24(2):147-58. doi: 10.1007/BF01961247.
The binding characteristics of several cytotoxic analogs of luteinizing hormone-releasing hormone (LH-RH) developed in our laboratory were examined in membranes from human breast cancer and estrogen independent MXT mammary cancer. Specific binding of [125I]D-Trp6-LH-RH and the cytotoxic LH-RH analog [125I]T-98 ([D-Lys6]LH-RH coupled to glutaryl-2-(hydroxymethyl)anthraquinone) (HMAQG) was demonstrated in membrane preparations from human breast and MXT mammary tumor cells. Ligand binding of T-98 was specific, saturable, and dependent on temperature, time, and plasma membrane concentration. Analysis of the binding data showed that in human breast cancer, interaction of [125I]T-98 was consistent with the presence of two classes of LH-RH receptors, one class showing high affinity and low capacity, and the other class showing low affinity and high capacity binding. In membranes from MXT mammary cancer, T-98 bound to one class of saturable, specific, noncooperative binding sites with high affinity and low capacity. The rates of association and dissociation for [125I]T-98 were calculated to be 4.757 x 10(8) M-1 min-1 and 0.016 min-1 (t1/2 = 38.7) in membranes from MXT mammary cancer. In human breast cancer, association rate constants (K1a and K1b) were 2.3 x 10(6) M-1 min-1 for binding to high affinity and 1.8 x 10(4) M-1 min-1 for binding to low affinity binding sites. Dissociation rate constants were K-1a = 0.0801 min-1 (t1/2a = 63.4 min) and K-1b = 0.0467 min-1 (t1/2b = 23.5 min), respectively. [125I]T-98 was not displaced by either unlabeled somatostatin or epidermal growth factor, but was displaced completely by unlabeled T-98 or [D-Trp6]LH-RH. The analysis of displacement curves of [D-Trp6]LH-RH by cytotoxic agonists and antagonists of LH-RH synthesized in our laboratory showed that T-121, AJ-11, T-120, T-133, and T-98 were the most potent in displacing [125I]D-Trp6-LH-RH from breast and MXT cancer membranes. Binding kinetics and analyses of displacement curves of [125I]D-Trp6-LH-RH and [125I]T-98 in membranes of human breast cancer and estrogen independent MXT mouse mammary cancer suggest that binding of the cytotoxic analog T-98 to the LH-RH receptor proceeds reversibly like that of its congeners without cytotoxic radicals. Our findings may provide a stimulus for further studies with LH-RH analogs carrying cytotoxic radicals.(ABSTRACT TRUNCATED AT 400 WORDS)
我们在实验室中研发了几种促黄体生成素释放激素(LH-RH)的细胞毒性类似物,对其结合特性进行了检测,检测对象为人乳腺癌和雌激素非依赖性MXT乳腺癌的细胞膜。在人乳腺和MXT乳腺肿瘤细胞的膜制剂中,证实了[125I]D-Trp6-LH-RH以及细胞毒性LH-RH类似物[125I]T-98([D-Lys6]LH-RH与戊二酰-2-(羟甲基)蒽醌(HMAQG)偶联)的特异性结合。T-98的配体结合具有特异性、可饱和性,且依赖于温度、时间和质膜浓度。结合数据分析表明,在人乳腺癌中,[125I]T-98的相互作用与两类LH-RH受体的存在一致,一类表现为高亲和力和低容量,另一类表现为低亲和力和高容量结合。在MXT乳腺癌的细胞膜中,T-98与一类具有高亲和力和低容量的可饱和、特异性、非协同结合位点结合。在MXT乳腺癌的细胞膜中,[125I]T-98的结合和解离速率分别计算为4.757×10(8) M-1 min-1和0.016 min-1(t1/2 = 38.7)。在人乳腺癌中,与高亲和力结合的结合速率常数(K1a和K1b)为2.3×10(6) M-1 min-1,与低亲和力结合位点结合的为1.8×10(4) M-1 min-1。解离速率常数分别为K-1a = 0.0801 min-1(t1/2a = 63.4 min)和K-1b = 0.0467 min-1(t1/2b = 23.5 min)。[125I]T-98既不被未标记的生长抑素也不被表皮生长因子取代,但可被未标记的T-98或[D-Trp6]LH-RH完全取代。我们实验室合成的LH-RH细胞毒性激动剂和拮抗剂对[D-Trp6]LH-RH置换曲线的分析表明,T-121、AJ-11、T-120、T-133和T-98在从乳腺和MXT癌细胞膜置换[125I]D-Trp6-LH-RH方面最有效。人乳腺癌和雌激素非依赖性MXT小鼠乳腺癌细胞膜中[125I]D-Trp6-LH-RH和[125I]T-98的结合动力学及置换曲线分析表明,细胞毒性类似物T-98与LH-RH受体的结合与其不含细胞毒性基团的同类物一样可逆进行。我们的发现可能会刺激对携带细胞毒性基团的LH-RH类似物进行进一步研究。(摘要截短至400字)